{"id":"capoxiri","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Hand-foot syndrome"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:27:18.072153","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CAPOXIRI combines capecitabine (a fluoropyrimidine prodrug converted to 5-FU) with oxaliplatin (a platinum-based alkylating agent). Capecitabine inhibits thymidylate synthase to disrupt DNA synthesis, while oxaliplatin forms DNA cross-links to prevent replication and transcription. Together, these agents provide synergistic cytotoxic activity against colorectal and other solid tumors.","oneSentence":"CAPOXIRI is a combination chemotherapy regimen that inhibits DNA synthesis and repair through multiple mechanisms to kill rapidly dividing cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:04:50.876Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (Phase 3 development)"}]},"_fixedFields":["pubmed(8)"],"trialDetails":[{"nctId":"NCT05646511","phase":"PHASE3","title":"TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2022-11-21","conditions":"Locally Advanced Rectal Cancer","enrollment":608},{"nctId":"NCT04097444","phase":"PHASE2","title":"CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC","status":"UNKNOWN","sponsor":"Chugai Pharmaceutical","startDate":"2019-10-11","conditions":"Metastatic Colorectal Cancer","enrollment":112},{"nctId":"NCT01760252","phase":"PHASE2","title":"Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol","status":"TERMINATED","sponsor":"Beth Israel Medical Center","startDate":"2011-12","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"recentPublications":[{"date":"2026 Feb","pmid":"41371459","title":"High-grade gastro-entero-pancreatic neuroendocrine neoplasms: An overlooked population in interventional clinical trials. A systematic review.","journal":"Critical reviews in oncology/hematology"},{"date":"2024 Sep 13","pmid":"38901425","title":"QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC.","journal":"Med (New York, N.Y.)"},{"date":"2023 Oct","pmid":"41647286","title":"Phase III trial of short-course radiotherapy followed by CAPOXIRI versus CAPOX in locally advanced rectal cancer: the ENSEMBLE trial.","journal":"ESMO gastrointestinal oncology"},{"date":"2021 Dec","pmid":"34019214","title":"Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.","journal":"Investigational new drugs"},{"date":"2020","pmid":"33014051","title":"Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece.","journal":"Journal of oncology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Experimental"],"phase":"phase_3","status":"active","brandName":"CAPOXIRI","genericName":"CAPOXIRI","companyName":"National Cancer Center Hospital East","companyId":"national-cancer-center-hospital-east","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CAPOXIRI is a combination chemotherapy regimen that inhibits DNA synthesis and repair through multiple mechanisms to kill rapidly dividing cancer cells. Used for Metastatic colorectal cancer (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}